CW Group Holdings Pty Ltd (Chemist Warehouse Group) → Sigma Healthcare Limited
completedSigma Healthcare and Chemist Warehouse Group entered a Merger Implementation Agreement structured as a reverse takeover: Sigma issued new shares (plus A$700 million cash) to Chemist Warehouse shareholders in exchange for 100% of CW Group Holdings, giving Chemist Warehouse shareholders roughly 85.75% of the combined, ASX-listed entity and providing Chemist Warehouse a backdoor listing. The deal was pitched at an implied combined enterprise value of about A$8.8 billion at announcement; Sigma's own market value was around A$5.8 billion at the time. It received ACCC clearance in November 2024, Chemist Warehouse shareholder approval (100% in favor) on January 29, 2025, and completed after Federal Court approval on February 3, 2025.
Chemist Warehouse founders (Jack Gance, Sam Gance, Mario Verrocchi) sought public-market scale and a listing without a traditional IPO, using Sigma — an existing ASX-listed pharmaceutical wholesaler/distributor — as the vehicle. The merger combined Chemist Warehouse's retail brand strength and buying power with Sigma's wholesale distribution and pharmacy franchise network (branded pharmacies including Amcal, Discount Drug Stores and Guardian), creating an integrated wholesaler-distributor-retailer with projected annual cost synergies of about A$60 million within four years.
Sigma's board and shareholders backed the deal for the scale, growth profile and market re-rating that combining with the far larger and more profitable Chemist Warehouse offered, versus Sigma continuing as a stand-alone, lower-margin pharmaceutical wholesaler facing tough competitive pressure.
Sigma Healthcare shares surged as much as 76.5% intraday on the announcement (December 12, 2023), the stock's biggest jump on record, closing near its highest level since October 2016. Shares of the merged entity rose a further ~9% on the first day of trading after completion in February 2025.
Framed as one of the largest and most significant M&A/capital-markets transactions in Australia in years, creating a combined group with a market capitalisation reported around A$34 billion by the time of completion (reflecting Sigma's post-announcement share price re-rating, not the announcement-date implied deal value). Proxy adviser Ownership Matters recommended shareholders vote in favour, calling terms fair and reasonable.
Deal mechanics
Rothschild & Co and Oaktower (financial advisors to Chemist Warehouse); Herbert Smith Freehills (lead legal advisor to Chemist Warehouse, with Bell Gully in New Zealand and A&L Goodbody in Ireland)
Gilbert + Tobin (legal advisor to Sigma, including on ASX listing requirements)
Reverse takeover via share issuance: Sigma issued new shares to CW Group Holdings shareholders plus A$700 million cash consideration, resulting in Chemist Warehouse shareholders holding approximately 85.75% of the combined group and existing Sigma shareholders retaining approximately 14.25%.
ACCC informal merger review cleared the deal in November 2024 (after the parties offered concessions to address competition concerns); Chemist Warehouse shareholders approved unanimously (100%) on January 29, 2025; Federal Court approval obtained February 3, 2025.
Comparable deals in Healthcare
Learn more
- Proposed Sigma Healthcare-Chemist Warehouse $8.8b merger gets ACCC green light
- Sigma healthcare completes its transformational merger with Chemist Warehouse
- Herbert Smith Freehills advises Chemist Warehouse on its A$34 billion merger with Sigma Healthcare
- Sigma Healthcare posts record jump on $5.8 billion merger with Chemist Warehouse
- Sigma Healthcare's merger with Chemist Warehouse completed